# The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

> **NCT06015282** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 7741 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Investigational aQIVc
- **BIOLOGICAL:** licensed QIVr
- **BIOLOGICAL:** licensed aQIV

## Key facts

- **NCT ID:** NCT06015282
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-03
- **Primary completion:** 2024-03-05
- **Final completion:** 2025-01-30
- **Target enrollment:** 7741 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015282, "The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06015282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*